CeriBell (NASDAQ:CBLL) CFO Sells $756,000.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 36,000 shares of the stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $21.00, for a total transaction of $756,000.00. Following the transaction, the chief financial officer directly owned 118,842 shares of the company’s stock, valued at $2,495,682. This represents a 23.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

CeriBell Price Performance

Shares of CBLL traded up $0.08 on Monday, reaching $21.38. The stock had a trading volume of 276,883 shares, compared to its average volume of 318,882. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $793.16 million, a PE ratio of -14.15 and a beta of 1.30. CeriBell, Inc. has a twelve month low of $10.01 and a twelve month high of $26.83. The firm has a 50-day moving average of $16.13 and a 200 day moving average of $14.78.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The business had revenue of $22.59 million during the quarter, compared to the consensus estimate of $21.78 million. Sell-side analysts expect that CeriBell, Inc. will post -2.46 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on CBLL shares. Cowen reissued a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. Weiss Ratings restated a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. JPMorgan Chase & Co. dropped their target price on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. BTIG Research restated a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research report on Monday, December 15th. Finally, Canaccord Genuity Group raised their target price on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and an average price target of $24.67.

Institutional Investors Weigh In On CeriBell

Large investors have recently made changes to their positions in the company. Sherbrooke Park Advisers LLC bought a new position in CeriBell during the third quarter worth about $135,000. Millennium Management LLC raised its position in shares of CeriBell by 41.8% in the third quarter. Millennium Management LLC now owns 666,448 shares of the company’s stock valued at $7,657,000 after buying an additional 196,299 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of CeriBell by 87.1% during the 3rd quarter. Bank of America Corp DE now owns 135,783 shares of the company’s stock worth $1,560,000 after purchasing an additional 63,215 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of CeriBell in the 3rd quarter valued at approximately $33,000. Finally, Two Sigma Investments LP increased its stake in shares of CeriBell by 81.0% in the 3rd quarter. Two Sigma Investments LP now owns 297,963 shares of the company’s stock valued at $3,424,000 after purchasing an additional 133,324 shares during the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.